Small Animal Studies Core Shared Resource ABSTRACT The Small Animal Studies Core (SASC) combines the resources available through the previously reviewed Small Animal Imaging Core with a new Animal Tumor Models component. This combined resource provides exceptional quality services for City of Hope Comprehensive Cancer Center (COHCCC) members for basic and translational preclinical studies in cancer biology, anti-cancer drug development, and stem cell therapeutic development. The Small Animal Imaging component of the SASC provides consultation, advanced imaging equipment, imaging services, hands-on training for COHCCC members, and support for protocol and grant preparation. Current systems in the Imaging Laboratory include two units for bioluminescence/fluorescence optical imaging (Ami X and Lago X from Spectral Instruments Imaging) and a PET/SPECT/CT trimodal scanner (Inveon from Siemens). These systems support molecular-based imaging to allow for the monitoring of cellular processes and the non-invasive assessment of pharmacokinetics and pharmacodynamics of therapeutic agents. Often the imaging techniques and targeting agents utilized are directly transferable to the clinical setting. The Animal Tumor Models component of the SASC has established patient-derived xenograft (PDX) models of breast, colorectal, lung, sarcoma, and gastric cancers in collaboration with COHCCC physician scientists and has developed next-generation humanized mouse models for research in cancer immunotherapy and in vivo drug metabolism/toxicity studies. The development of PDX models supports precision medicine by allowing investigators to evaluate tumor growth and therapeutic response for individual patients. The Animal Tumor Models component also provides specialized drug delivery services, training for in vivo procedures, and support for protocol preparation and grant development. The SASC is co-directed by Dr. David Colcher, a Professor in the Department of Molecular Immunology, and Dr. Jun Wu, an Associate Research Professor of Comparative Medicine, and is supported by highly qualified staff that maintain and operate the instrumentation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. The SASC occupies three rooms within the 29,000 sq. ft. Parvin Building for animal experiments and two rooms in Huntington Lab for tumor cell and reagent preparation. iLab software is used to schedule services, monitor instrument use, and manage billing within the SASC. Over the previous five years, the SASC was used by 80 unique investigators, including 58 CC members. Of the 58 CC members, 48 (83%) had peer-reviewed funding. As of this report, the SASC provides ongoing support to 12 NIH-funded projects totaling $5.6M per year in direct costs to the COHCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-35
Application #
9491626
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-04-20
Budget End
2018-11-30
Support Year
35
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications